tiprankstipranks
Trending News
More News >
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558)
:1558
Hong Kong Market

YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (1558) Price & Analysis

Compare
0 Followers

1558 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

2.23%94.68%
Insiders
2.23%
Mutual Funds
― Other Institutional Investors
94.68% Public Companies and
Individual Investors

1558 FAQ

What was YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price range in the past 12 months?
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H lowest stock price was HK$7.92 and its highest was HK$15.54 in the past 12 months.
    What is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s market cap?
    YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s market cap is HK$13.11B.
      When is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s upcoming earnings report date?
      YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s upcoming earnings report date is Aug 22, 2025 which is in 51 days.
        How were YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s earnings last quarter?
        YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H released its earnings results on Mar 28, 2025. The company reported -HK$0.249 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.249.
          Is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H overvalued?
          According to Wall Street analysts YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H pay dividends?
            YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H pays a Quarterly dividend of HK$0.114 which represents an annual dividend yield of N/A. See more information on YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H dividends here
              What is YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s EPS estimate?
              YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H have?
              YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H has 653,767,700 shares outstanding.
                What happened to YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H’s price movement after its last earnings report?
                YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H reported an EPS of -HK$0.249 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.729%.
                  Which hedge fund is a major shareholder of YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H?
                  Currently, no hedge funds are holding shares in HK:1558

                  YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H Stock Smart Score

                  Company Description

                  YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H

                  YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, and cardiovascular diseases in the People's Republic of China. It also manufactures and sells active pharmaceutical ingredients; researches and develops medical devices and drugs, as well as biotechnology; and provides medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. It has a strategic cooperation framework agreement with Alibaba Health Technology (China) Limited to carry out influenza special projects; Jointown Pharmaceutical Group Co., Ltd.; Guangdong Yihao Pharmaceutical Co., Ltd.; and Shenzhen HEC Industrial Development Co., Ltd, as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China. YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a subsidiary of Guangdong HEC Technology Holding Co., Ltd.

                  1558 Stock 12 Month Forecast

                  Average Price Target

                  HK$14.00
                  ▼(-6.04%Downside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"HK$7","9":"HK$9","11":"HK$11","13":"HK$13","15":"HK$15"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,9,11,13,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.48,12.596923076923078,12.713846153846154,12.830769230769231,12.947692307692307,13.064615384615385,13.181538461538462,13.298461538461538,13.415384615384616,13.532307692307693,13.649230769230769,13.766153846153847,13.883076923076922,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.48,12.596923076923078,12.713846153846154,12.830769230769231,12.947692307692307,13.064615384615385,13.181538461538462,13.298461538461538,13.415384615384616,13.532307692307693,13.649230769230769,13.766153846153847,13.883076923076922,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.48,12.596923076923078,12.713846153846154,12.830769230769231,12.947692307692307,13.064615384615385,13.181538461538462,13.298461538461538,13.415384615384616,13.532307692307693,13.649230769230769,13.766153846153847,13.883076923076922,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.36,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.3,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.48,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":11.24,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":10.68,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":12.96,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.9,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.99,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.22,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.66,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.66,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.48,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  China Traditional Chinese Medicine Holdings Co
                  Consun Pharmaceutical Group Ltd.
                  Jacobson Pharma Corporation Limited
                  China Shineway Pharmaceutical Group Limited
                  Shandong Xinhua Pharmaceutical Company Limited Class H
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis